Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) gapped down before the market opened on Friday .The stock had previously closed at $28.17, but opened at $27.00. Galapagos shares last traded at $26. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Hedge funds and other institutional investors own 32.46% of the company’s stock. Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GET MORE AI-GENERATED SIGNALS: January 15, 2025, 11:02 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

It was a busy week for the biotech sector with updates from quite a few players. While pharma bigwig Amgen (NASDAQ:AMGN) agreed to buy Celgene’s (NASDAQ:CELG) Otezla, ...

Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...